Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
Portfolio Pulse from
Akebia Therapeutics (AKBA) reported a Q3 loss of $0.10 per share, missing the Zacks Consensus Estimate of a $0.05 loss. This is a larger loss compared to $0.08 per share a year ago.
November 07, 2024 | 2:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Akebia Therapeutics reported a larger than expected Q3 loss of $0.10 per share, missing the consensus estimate of $0.05 and increasing from last year's $0.08 loss.
The reported loss of $0.10 per share is worse than the expected $0.05 loss, indicating a negative earnings surprise. This is likely to impact the stock price negatively in the short term as it reflects poorer financial performance than anticipated.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100